Liprostin Group, Inc.

Our patented, drug delivery system, Liprostin, encapsulates Prostaglandin 1 in a liposome which can treat deadly COVID-19 Lung inflammation and cytokine storms.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Houston, TX, USA
  • Currency USD
  • Founded February 2018
  • Employees 2
  • Incorporation Type C-corp
  • Website LiprostinGroup.com

Company Summary

We licensed the Liprostin patent, a liposomal drug delivery technology that enhances Alprostadil, an FDA generic drug, a potent suppressor of inflammation, vasodilator, and platelet anti-aggregator. Our clinical trials show it can treat Peripheral Artery Disease and COVID inflammatory lung problem / cytokine storms. Funding is for a COVID-FDA Emergency Proof of Concept. Our exit will be to sublicense our technology to a Bio-Pharma partner.

Team

  • Bruce Badeau
    Venture Architect – Co-CEO, Director-Founder

    • Wrote AngioSoma business plan, predecessor of Liprostin Group
    • Led move away from public entity which controlled David Summers IP
    • Organized Liprostin Group, recruited founders, licensed Summers I
    • Founded First Sovereign Equity Research 1996 -- Financial Advisors
    We are financial advisors, write deal making software (SharkCapTable), valuations, business plans, and structure companies to raise capital, or do acquisitions or divestitures

Advisors

  • Gerald Yakatan
    Jackie R. See M.D., F.A.C.C. – Co Principal Investigator Board-Certified Internist, Fellow of American College of Cardiology Pioneer of Interventional Cardiology Founded the teaching program of Interventional Cardiology at UC Irvine School of Medicine
    Unconfirmed
    Undurti Das

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free